Clarity Pharmaceuticals achieves recruitment target for phase II SAR-Bombesin prostate cancer trial
Clinical-stage radiopharma company Clarity Pharmaceuticals (ASX:CU6) has imaged 50 patients with Cu-SAR-Bombesin…
Fri, 03 May | Last | Change |
1:47pm | 7,634.4 | 47.4 |
Currently Trading at Fri, 03 May 1:49pm |
S&P/ASX Sm. Ords. | 2,999.8 | 23.5 | 0.79% |
All Ordinaries | 7,902.4 | 53.0 | 0.68% |
S&P/ASX 100 | 6,407.3 | 38.9 | 0.61% |
RCR | RINCON RESOURCES LIMITED | 13.5¢ | 42.1% |
PPK | PPK GROUP LIMITED | 57.0¢ | 32.6% |
OSX | OSTEOPORE LIMITED | 38.0¢ | 26.7% |
ACW | ACTINOGEN MEDICAL LIMITED | 3.0¢ | 21.1% |
RFT | RECTIFIER TECHNOLOGIES LTD | 1.2¢ | 20.0% |
STM | SUNSTONE METALS LTD | 1.2¢ | 17.9% |